Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication

Background: Once-daily treatment formulation is associated with better adherence in comparison to more complex medication regimens. The study aimed to detect the extent of adherence to pharmacotherapy in Parkinson disease (PD) patients who take a minimum of three daily doses of drugs, and to identif...

Full description

Bibliographic Details
Main Authors: Igor Straka, Michal Minár, Matej Škorvánek, Milan Grofik, Katarína Danterová, Ján Benetin, Egon Kurča, Andrea Gažová, Veronika Boleková, Kathryn A. Wyman-Chick, Ján Kyselovič, Peter Valkovič
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-07-01
Series:Frontiers in Neurology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2019.00799/full
id doaj-acc1f572ea014b36a3390cc5112c38fb
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Igor Straka
Michal Minár
Matej Škorvánek
Milan Grofik
Katarína Danterová
Ján Benetin
Egon Kurča
Andrea Gažová
Veronika Boleková
Veronika Boleková
Kathryn A. Wyman-Chick
Ján Kyselovič
Peter Valkovič
Peter Valkovič
spellingShingle Igor Straka
Michal Minár
Matej Škorvánek
Milan Grofik
Katarína Danterová
Ján Benetin
Egon Kurča
Andrea Gažová
Veronika Boleková
Veronika Boleková
Kathryn A. Wyman-Chick
Ján Kyselovič
Peter Valkovič
Peter Valkovič
Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication
Frontiers in Neurology
adherence
antiparkinson drugs
non-motor symptoms
Parkinson's disease
quality of life
author_facet Igor Straka
Michal Minár
Matej Škorvánek
Milan Grofik
Katarína Danterová
Ján Benetin
Egon Kurča
Andrea Gažová
Veronika Boleková
Veronika Boleková
Kathryn A. Wyman-Chick
Ján Kyselovič
Peter Valkovič
Peter Valkovič
author_sort Igor Straka
title Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication
title_short Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication
title_full Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication
title_fullStr Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication
title_full_unstemmed Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication
title_sort adherence to pharmacotherapy in patients with parkinson's disease taking three and more daily doses of medication
publisher Frontiers Media S.A.
series Frontiers in Neurology
issn 1664-2295
publishDate 2019-07-01
description Background: Once-daily treatment formulation is associated with better adherence in comparison to more complex medication regimens. The study aimed to detect the extent of adherence to pharmacotherapy in Parkinson disease (PD) patients who take a minimum of three daily doses of drugs, and to identify factors associated with lower levels of adherence.Methods: The cohort was selected from non-demented PD patients. The 8-Item Morisky Medication Adherence Scale (MMAS-8), 8-Item Parkinson's Disease Questionnaire (PDQ-8), Geriatric Depression Scale (GDS), Non-Motor Symptom Assessment Scale (NMSS), 9-Item Wearing-off Questionnaire (WOQ-9), MDS-UPDRS III (motor examination), and IV (motor complications) scales were used in this study.Results: From a total of 124 subjects, 33.9% reported a high level of adherence, 29.8% reported a medium level of adherence, and 36.3% reported a low level of adherence to their pharmacotherapy. The level of non-adherence correlated with gender, longer disease duration, higher scores of PDQ-8, NMSS, WOQ-9, and MDS-UPDRS IV. Detailed analysis of NMSS demonstrated a correlation between the level of adherence and domains sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, and urinary symptoms. Independent risk factors for non-adherence were excessive daytime sleepiness, anhedonia, and forgetfulness.Conclusion: Non-adherence to more complicated medication regimens is frequent in PD patients and is associated with gender, longer PD duration, poorer quality of life, frequency and severity of non-motor symptoms, and more severe motor and non-motor fluctuations. Non-adherence was predicted by non-motor symptoms including fatigue, mood disturbances, and subjective cognitive complaints.
topic adherence
antiparkinson drugs
non-motor symptoms
Parkinson's disease
quality of life
url https://www.frontiersin.org/article/10.3389/fneur.2019.00799/full
work_keys_str_mv AT igorstraka adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication
AT michalminar adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication
AT matejskorvanek adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication
AT milangrofik adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication
AT katarinadanterova adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication
AT janbenetin adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication
AT egonkurca adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication
AT andreagazova adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication
AT veronikabolekova adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication
AT veronikabolekova adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication
AT kathrynawymanchick adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication
AT jankyselovic adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication
AT petervalkovic adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication
AT petervalkovic adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication
_version_ 1725978844953837568
spelling doaj-acc1f572ea014b36a3390cc5112c38fb2020-11-24T21:26:34ZengFrontiers Media S.A.Frontiers in Neurology1664-22952019-07-011010.3389/fneur.2019.00799473505Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of MedicationIgor Straka0Michal Minár1Matej Škorvánek2Milan Grofik3Katarína Danterová4Ján Benetin5Egon Kurča6Andrea Gažová7Veronika Boleková8Veronika Boleková9Kathryn A. Wyman-Chick10Ján Kyselovič11Peter Valkovič12Peter Valkovič13Second Department of Neurology, Comenius University in Bratislava Faculty of Medicine, University Hospital Bratislava, Bratislava, SlovakiaSecond Department of Neurology, Comenius University in Bratislava Faculty of Medicine, University Hospital Bratislava, Bratislava, SlovakiaDepartment of Neurology, Pavol Jozef Safarik University in Kosice Faculty of Medicine, University Hospital of Louis Pasteur, Košice, SlovakiaDepartment of Neurology, Comenius University in Bratislava Jessenius Faculty of Medicine in Martin, University Hospital Martin, Martin, SlovakiaDepartment of Neurology, University Hospital Bratislava, Slovak Medical University, Bratislava, SlovakiaDepartment of Neurology, University Hospital Bratislava, Slovak Medical University, Bratislava, SlovakiaDepartment of Neurology, Comenius University in Bratislava Jessenius Faculty of Medicine in Martin, University Hospital Martin, Martin, SlovakiaComenius University in Bratislava Faculty of Medicine, Institute of Pharmacology and Clinical Pharmacology, Bratislava, SlovakiaSecond Department of Neurology, Comenius University in Bratislava Faculty of Medicine, University Hospital Bratislava, Bratislava, SlovakiaPan-European University Faculty of Psychology, Institute of Clinical Psychology, Bratislava, SlovakiaHealthPartners Neuroscience Center, Saint Paul, MN, United StatesFifth Department of Internal Medicine, Comenius University in Bratislava Faculty of Medicine, University Hospital Bratislava, Bratislava, SlovakiaSecond Department of Neurology, Comenius University in Bratislava Faculty of Medicine, University Hospital Bratislava, Bratislava, SlovakiaCentre of Experimental Medicine, Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, Bratislava, SlovakiaBackground: Once-daily treatment formulation is associated with better adherence in comparison to more complex medication regimens. The study aimed to detect the extent of adherence to pharmacotherapy in Parkinson disease (PD) patients who take a minimum of three daily doses of drugs, and to identify factors associated with lower levels of adherence.Methods: The cohort was selected from non-demented PD patients. The 8-Item Morisky Medication Adherence Scale (MMAS-8), 8-Item Parkinson's Disease Questionnaire (PDQ-8), Geriatric Depression Scale (GDS), Non-Motor Symptom Assessment Scale (NMSS), 9-Item Wearing-off Questionnaire (WOQ-9), MDS-UPDRS III (motor examination), and IV (motor complications) scales were used in this study.Results: From a total of 124 subjects, 33.9% reported a high level of adherence, 29.8% reported a medium level of adherence, and 36.3% reported a low level of adherence to their pharmacotherapy. The level of non-adherence correlated with gender, longer disease duration, higher scores of PDQ-8, NMSS, WOQ-9, and MDS-UPDRS IV. Detailed analysis of NMSS demonstrated a correlation between the level of adherence and domains sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, and urinary symptoms. Independent risk factors for non-adherence were excessive daytime sleepiness, anhedonia, and forgetfulness.Conclusion: Non-adherence to more complicated medication regimens is frequent in PD patients and is associated with gender, longer PD duration, poorer quality of life, frequency and severity of non-motor symptoms, and more severe motor and non-motor fluctuations. Non-adherence was predicted by non-motor symptoms including fatigue, mood disturbances, and subjective cognitive complaints.https://www.frontiersin.org/article/10.3389/fneur.2019.00799/fulladherenceantiparkinson drugsnon-motor symptomsParkinson's diseasequality of life